Evidence map›Paper›PMID 27803125›Full record

ArticleBioscience reports2016

Efficient and simple approach to in vitro culture of primary epithelial cancer cells.

Karolina Janik, Marta Popeda, Joanna Peciak, Kamila Rosiak, Maciej Smolarz, Cezary Treda, Piotr Rieske, Ewelina Stoczynska-Fidelus, Magdalena Ksiazkiewicz

Abstract read
In one paragraph

Article in Bioscience reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Review
  2. Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary.Molecular therapy : the journal of the American Society of Gene Therapy · 2024
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Karolina JanikResearch and Development Unit, Celther Polska Ltd., Milionowa 23, 93-193 Lodz, Poland karolina.janik@celther.com.
Marta PopedaResearch and Development Unit, Celther Polska Ltd., Milionowa 23, 93-193 Lodz, Poland.
Joanna PeciakResearch and Development Unit, Celther Polska Ltd., Milionowa 23, 93-193 Lodz, Poland.
Kamila RosiakResearch and Development Unit, Celther Polska Ltd., Milionowa 23, 93-193 Lodz, Poland.
Maciej SmolarzResearch and Development Unit, Celther Polska Ltd., Milionowa 23, 93-193 Lodz, Poland.
Cezary TredaResearch and Development Unit, Celther Polska Ltd., Milionowa 23, 93-193 Lodz, Poland.
Piotr RieskeResearch and Development Unit, Celther Polska Ltd., Milionowa 23, 93-193 Lodz, Poland.
Ewelina Stoczynska-FidelusResearch and Development Unit, Celther Polska Ltd., Milionowa 23, 93-193 Lodz, Poland.
Magdalena KsiazkiewiczResearch and Development Unit, Celther Polska Ltd., Milionowa 23, 93-193 Lodz, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary cancer cells constitute a favourable testing platform for in vitro research in oncology field as they reflect tumour state more accurately than the most commonly employed stable cell lines. Unfortunately, due to limited availability of material and difficulties with protocols validation, primary models are rarely implemented into laboratory practice.We have compared protocols for primary cultures, differing in media components and plate coatings. In terms of culture establishment, application of Geltrex® coating demonstrated equal efficiency to feeder layer (83% compared with 72% successfully established breast and 80% compared with 80% prostate tumour specimens), yet it was substantially less complicated and easier to validate. Both Geltrex® coating and tissue-specific primary cell medium were permanently required to successfully maintain primary epithelial prostate cancer cells (PEPCs) in culture. In case of primary epithelial breast cancer cells (PEBCs), collagen I coating enabled to obtain comparable number of passages to Geltrex® coating (P=0.438). Commercial primary cell media demonstrated lower efficiency than tissue-specific ones (PEPCs-5 compared with 8 and PEBCs-6 compared with 9 passages). Interestingly, both analysed tumour types were unsusceptible to induction of culture lifespan extension when transduced with SV40LT, BMI-1 or hEST2 genes, commonly applied as potential immortalizing agents.In conclusion, the approach based on extracellular matrix reconstitution and tissue-specific primary cell media is easy to validate and provides in vitro expansion sufficient for analytical purposes (approximately 8 passages). Therefore, it may facilitate implementation of hardly available experimental models for a variety of analyses.

Indexed as

AnimalsBreastBreast NeoplasmsCell LineCollagen Type IEpithelial CellsExtracellular MatrixFemaleHumansMaleMiceNIH 3T3 CellsProstateProstatic NeoplasmsProto-Oncogene ProteinsTelomeraseCollagen Type IProto-Oncogene ProteinsTelomerasebreast cancerextracellular matrixprimary cancer cell culturesprostate cancerRho kinase (ROCK) inhibitor

Identifiers

PMID27803125
PMCPMC5146827

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.